ReviewClinical pharmacokinetics2001
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.
Review in Clinical pharmacokinetics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 118 citations in OpenAlex.
- Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.Drug design, development and therapy · 2018Trial
- Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Trial
- A unique iontophoretic patch for optimal transdermal delivery of sumatriptan.Pharmaceutical research · 2007Trial
- Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.Journal of neurology · 2007Trial
- Rimegepant for vestibular and cochlear symptoms associated with vertigo in a real-world retrospective study.iScience · 2026Article
- Sex-specific considerations in migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- miR-197, miR-101, and miR-143 and Pro-Inflammatory Cytokines in Migraine.Journal of clinical medicine · 2025Article
- Influence of metabolic state and body composition on the action of pharmacological treatment of migraine.The journal of headache and pain · 2024Review
- Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study.Neurology · 2023Article
- Metabolism of sumatriptan revisited.Pharmacology research & perspectives · 2023Article
- Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization.AAPS PharmSciTech · 2022Article
- Sex-Specific Pharmacotherapy for Migraine: A Narrative Review.Frontiers in neuroscience · 2020Review
- Economic burden of migraine in Latvia and Lithuania: direct and indirect costs.BMC public health · 2019Article
- Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- 17-β-Estradiol induces spreading depression and pain behavior in alert female rats.Oncotarget · 2017Article
- Article
- Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.Therapeutic advances in neurological disorders · 2016Review
- Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route.International scholarly research notices · 2014Article
- Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.Nature medicine · 2012Article
- Preparation and evaluation of tubular micelles of pluronic lecithin organogel for transdermal delivery of sumatriptan.AAPS PharmSciTech · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current approach to antimigraine therapy comprises potent serotonin 5-HT1B/1D receptor agonists collectively termed triptans. Sumatriptan was the first of these compounds to be developed, and offered improved efficacy and tolerability over ergot-derived compounds. The development of sumatriptan was quickly followed by a number of 'second generation' triptan compounds, characterised by improved pharmacokinetic properties and/or tolerability profiles. Triptans are believed to effect migraine relief by binding to serotonin (5-hydroxy-tryptamine) receptors in the brain, where they act to induce vasoconstriction of extracerebral blood vessels and also reduce neurogenic inflammation. Although the pharmacological mechanism of the triptans is similar, their pharmacokinetic properties are distinct. For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan). Clearly, such diverse pharmacokinetic properties will influence the effectiveness of the compounds and favour the prescription of one over another in different patient populations. This article reviews the pharmacological properties of the triptans (time to peak plasma concentration, half-life, bioavailability and receptor binding) and relates these properties to efficacy and time of onset. It also considers the effects of concomitant medication, food, age and disease on the pharmacokinetics of the compounds. In addition, the relative merits, such as headache recurrence, tolerability and route of administration, are discussed. Finally, the performance of the triptans is considered in the context of direct head-to-head comparative trials that have assessed the efficacy profile of the compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.